Last reviewed · How we verify
Preservative-Free Tafluprost
Tafluprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
Tafluprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Preservative-Free Tafluprost |
|---|---|
| Also known as | MK2452 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Tafluprost mimics the action of prostaglandin F by activating FP receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the unconventional (uveoscleral) pathway, leading to decreased intraocular pressure. The preservative-free formulation aims to reduce ocular surface irritation and improve tolerability in patients requiring chronic topical therapy.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation/discomfort
- Increased iris pigmentation
- Eyelash growth (hypertrichosis)
- Periocular skin darkening
Key clinical trials
- A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
- From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy (NA)
- Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing (PHASE4)
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy (PHASE4)
- Tafluprost Preservative Free Switch Study (PHASE4)
- Preservative-free Tafluprost Eye Drops in Newly Diagnosed Patients With Glaucoma (PHASE2, PHASE3)
- Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Preservative-Free Tafluprost CI brief — competitive landscape report
- Preservative-Free Tafluprost updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI